<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941161</url>
  </required_header>
  <id_info>
    <org_study_id>DMGlime-04</org_study_id>
    <nct_id>NCT00941161</nct_id>
  </id_info>
  <brief_title>Effect of Oral Combination Therapy in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determinate the effect of combined oral therapy of long acting
      metformin/glimepiride in a single dose in patients with type 2 diabetes mellitus and
      monotherapy failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized double-blind clinical trial, to determine the effect of combined therapy of oral
      prolonged-release metformin/glimepiride in a single dosage form on fasting glucose and HbA1c.
      Patients will be included in this study are patients with diabetes mellitus and secondary
      failure to monotherapy. Will also assess the effect of combined therapy on the oral lipid
      profile (total cholesterol, LDL, HDL, VLDL, Triglycerides) and on the sensitivity and insulin
      secretion. We evaluate the clinical measurements, laboratory and safety during 3 months,
      through the allocation of subjects to three study groups (metformin, glimepiride and
      metformin extended release / glimepiride)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting glucose, HbA1c</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>total cholesterol, C-LDL, C-HDL, triglycerides, VLDL, insulin</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>long acting Metformin/Glimepiride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin hydrocloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glimepiride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin/glimepiride combination</intervention_name>
    <description>long acting metformin/glimepiride 1g/2mg</description>
    <arm_group_label>combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL</description>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL</description>
    <arm_group_label>glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40 to 65 years old

          -  Ability to communicate and to meet the requirements of the study

          -  Signed Written Informed Consent before to conducting any study

          -  Body Mass Index (BMI) = 25-40kg/m2

          -  Stable weight in the past three months (variability &lt;5%)

          -  Meal plan and monotherapy with oral hypoglycaemic fails

          -  Fasting glucose = 130-270 mg/dL

          -  HbA1c &gt; 7%

          -  isocaloric diet with a minimum of 250 grams of carbohydrates per day in the three days
             prior to making the laboratory tests

        Exclusion Criteria:

          -  Suspected or confirmed pregnancy

          -  Nursing

          -  Inability to secure the non-pregnant during the study duration

          -  Hypersensitivity to any of the drugs under study

          -  Treatment with oral hypoglycemic or insulin

          -  Consumption of substance with toxic effects on any organ system

          -  Liver failure, heart failure, kidney failure or thyroid disease

          -  Chronic intake of alcohol

          -  Periods of acute or chronic diarrhea or vomiting

          -  Consumption of antifungal azoles, MAO inhibitors, nifedipine,furosemide, amiloride,
             digoxin, procainamide, quinidine, quinine, triamterene and vancomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Gonzalez, M.D., Master</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Silanes S.A. de C.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Gonzalez, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esperanza Martínez, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>International Diabetes Federation / International Association for the Study of Obesity. Diabetes and Obesity 11-21, 2004</citation>
  </reference>
  <reference>
    <citation>Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999 Oct;34(4):1348-59. Review.</citation>
    <PMID>10520820</PMID>
  </reference>
  <reference>
    <citation>Tseng KH. Standards of medical care in diabetes--2006: response to the American Diabetes Association. Diabetes Care. 2006 Nov;29(11):2563-4; author reply 2564-5.</citation>
    <PMID>17065711</PMID>
  </reference>
  <reference>
    <citation>Cohen J, Colman P. Type 2 diabetes--the pharmacotherapy of glycaemic control and risk factor modification. Aust Fam Physician. 2006 Jun;35(6):380-4.</citation>
    <PMID>16751851</PMID>
  </reference>
  <reference>
    <citation>Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006 Aug;49(8):1711-21. Erratum in: Diabetologia. 2006 Nov;49(11):2816-8.</citation>
    <PMID>16802130</PMID>
  </reference>
  <reference>
    <citation>Riddle M. Combining sulfonylureas and other oral agents. Am J Med. 2000 Apr 17;108 Suppl 6a:15S-22S. Review.</citation>
    <PMID>10764846</PMID>
  </reference>
  <reference>
    <citation>Bermúdez-Pirela VJ, Cano C, Medina MT, Souki A, Lemus MA, Leal EM, Seyfi HA, Cano R, Ciscek A, Bermúdez-Arias F, Contreras F, Israili ZH, Hernández-Hernández R, Valasco M. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus. Am J Ther. 2007 Mar-Apr;14(2):194-202.</citation>
    <PMID>17414590</PMID>
  </reference>
  <reference>
    <citation>González-Ortiz M, Martínez-Abundis E; Grupo para el Tratamiento de la Diabetes Mellitus con Combinaciones. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy]. Rev Invest Clin. 2004 May-Jun;56(3):327-33. Spanish.</citation>
    <PMID>15612515</PMID>
  </reference>
  <reference>
    <citation>Mandal U, Gowda V, Ghosh A, Selvan S, Solomon S, Pal TK. Formulation and optimization of sustained release matrix tablet of metformin HCl 500 mg using response surface methodology. Yakugaku Zasshi. 2007 Aug;127(8):1281-90.</citation>
    <PMID>17666882</PMID>
  </reference>
  <reference>
    <citation>Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006 Apr;29(4):759-64.</citation>
    <PMID>16567811</PMID>
  </reference>
  <reference>
    <citation>Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996 Feb 29;334(9):574-9. Review.</citation>
    <PMID>8569826</PMID>
  </reference>
  <reference>
    <citation>McCall AL. Clinical review of glimepiride. Expert Opin Pharmacother. 2001 Apr;2(4):699-713. Review.</citation>
    <PMID>11336617</PMID>
  </reference>
  <reference>
    <citation>Schneider J. An overview of the safety and tolerance of glimepiride. Horm Metab Res. 1996 Sep;28(9):413-8. Review.</citation>
    <PMID>8911975</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>May 17, 2010</last_update_submitted>
  <last_update_submitted_qc>May 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jorge Gonzalez Canudas, M.D.</name_title>
    <organization>Laboratorios Silanes, S.A. de C.V.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

